Abstract
Number-needed-to-treat (NNT) and cost data were combined to assess the cost-effectiveness of branded disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS), and compare the incremental healthcare costs per relapse avoided and healthcare cost savings of ozanimod with commonly used oral and injectable DMTs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
